Treatment of acute hepatitis C with interferon alfa-2b
- PMID: 11794193
- DOI: 10.1056/NEJMoa011232
Treatment of acute hepatitis C with interferon alfa-2b
Abstract
Background: In people who are infected with the hepatitis C virus (HCV) chronic infection often develops and is difficult to eradicate. We sought to determine whether treatment during the acute phase could prevent the development of chronic infection.
Methods: Between 1998 and 2001, we identified 44 patients throughout Germany who had acute hepatitis C. Patients received 5 million U of interferon alfa-2b subcutaneously daily for 4 weeks and then three times per week for another 20 weeks. Serum HCV RNA levels were measured before and during therapy and 24 weeks after the end of therapy.
Results: The mean age of the 44 patients was 36 years; 25 were women. Nine became infected with HCV through intravenous drug use, 14 through a needle-stick injury, 7 through medical procedures, and 10 through sexual contact; the mode of infection could not be determined in 4. The average time from infection to the first signs or symptoms of hepatitis was 54 days, and the average time from infection until the start of therapy was 89 days. At the end of both therapy and follow-up, 43 patients (98 percent) had undetectable levels of HCV RNA in serum and normal serum alanine aminotransferase levels. Levels of HCV RNA became undetectable after an average of 3.2 weeks of treatment. Therapy was well tolerated in all but one patient, who stopped therapy after 12 weeks because of side effects.
Conclusions: Treatment of acute hepatitis C with interferon alfa-2b prevents chronic infection.
Comment in
-
Therapy for acute hepatitis C.N Engl J Med. 2001 Nov 15;345(20):1495-7. doi: 10.1056/NEJM200111153452013. N Engl J Med. 2001. PMID: 11794202 No abstract available.
-
Treatment of acute hepatitis C with interferon alfa-2b.N Engl J Med. 2002 Apr 4;346(14):1091-2. doi: 10.1056/NEJM200204043461414. N Engl J Med. 2002. PMID: 11932480 No abstract available.
-
Treatment of acute hepatitis C with interferon alfa-2b.N Engl J Med. 2002 Apr 4;346(14):1091-2. N Engl J Med. 2002. PMID: 11936120 No abstract available.
-
Treatment of acute hepatitis C with interferon alfa-2b.N Engl J Med. 2002 Apr 4;346(14):1091-2. N Engl J Med. 2002. PMID: 11936121 No abstract available.
-
Treatment of acute hepatitis C with interferon alfa-2b.N Engl J Med. 2002 Apr 4;346(14):1091-2. N Engl J Med. 2002. PMID: 11936122 No abstract available.
-
Acute hepatitis C: to treat or not to treat?Hepatology. 2002 Jun;35(6):1538-40. doi: 10.1002/hep.510350631. Hepatology. 2002. PMID: 12029642 No abstract available.
Similar articles
-
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.N Engl J Med. 1998 Nov 19;339(21):1485-92. doi: 10.1056/NEJM199811193392101. N Engl J Med. 1998. PMID: 9819446 Clinical Trial.
-
Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.Gastroenterology. 2006 Mar;130(3):632-8. doi: 10.1053/j.gastro.2006.01.034. Gastroenterology. 2006. PMID: 16530503 Clinical Trial.
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.N Engl J Med. 2002 Sep 26;347(13):975-82. doi: 10.1056/NEJMoa020047. N Engl J Med. 2002. PMID: 12324553 Clinical Trial.
-
Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.Hepatology. 1997 Sep;26(3 Suppl 1):101S-107S. doi: 10.1002/hep.510260718. Hepatology. 1997. PMID: 9305673 Review.
-
[Acute hepatitis C: response to treatment with interferon-alpha plus ribavirin].Gastroenterol Hepatol. 2002 Oct;25(8):483-6. Gastroenterol Hepatol. 2002. PMID: 12361528 Review. Spanish.
Cited by
-
Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users.Epidemiol Infect. 2007 Jan;135(1):144-50. doi: 10.1017/S0950268806006388. Epub 2006 May 17. Epidemiol Infect. 2007. PMID: 16707030 Free PMC article.
-
Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management.Drugs. 2006;66(2):155-74. doi: 10.2165/00003495-200666020-00003. Drugs. 2006. PMID: 16451091 Review.
-
Treating viral hepatitis C: efficacy, side effects, and complications.Gut. 2006 Sep;55(9):1350-9. doi: 10.1136/gut.2005.076646. Gut. 2006. PMID: 16905701 Free PMC article. Review.
-
Acute hepatitis C virus infection: a chronic problem.Hepatology. 2008 Jan;47(1):321-31. doi: 10.1002/hep.21902. Hepatology. 2008. PMID: 18161707 Free PMC article. Review. No abstract available.
-
HIV/hepatitis prevention in drug abuse treatment programs: guidance from research.Sci Pract Perspect. 2002 Jul;1(1):4-11. doi: 10.1151/spp02114. Sci Pract Perspect. 2002. PMID: 18567957 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical